NIA Impact Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

NIA Impact Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.92M	Sell	15,490 -2,148	-12%	-$1M	3.08%	7
2025 Q4	$8M	Buy	17,638 +1,705	+11%	+$735K	2.68%	6
2025 Q3	$6.24M	Buy	15,933 +46	+0.3%	+$19.2K	2.03%	16
2025 Q2	$7.07M	Sell	15,887 -45	-0.3%	-$20.7K	2.44%	12
2025 Q1	$7.72M	Hold	15,932	–	–	2.87%	5
2024 Q4	$6.42M	Sell	15,932 -1,395	-8%	-$647K	2.09%	16
2024 Q3	$8.06M	Sell	17,327 -1,452	-8%	-$697K	2.68%	9
2024 Q2	$8.8M	Sell	18,779 -978	-5%	-$424K	3.16%	5
2024 Q1	$8.26M	Buy	+19,757	New	+$8.35M	3.29%	5
2023 Q2	$6.96M	Sell	20,046 -180	-0.9%	-$60.6K	3.96%	5
2023 Q1	$6.37M	Buy	20,226 +1,051	+5%	+$315K	3.44%	7
2022 Q4	$5.54M	Buy	19,175 +2,023	+12%	+$617K	3.22%	6
2022 Q3	$4.97M	Buy	17,152 +9,533	+125%	+$2.74M	3.06%	7
2022 Q2	$2.15M	Buy	+7,619	New	+$2.04M	1.29%	30

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NIA Impact Advisors's VRTX Position: Q1 2026 in Review

NIA Impact Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, selling an estimated $1M and leaving 15,490 shares worth $6.92M. The position accounts for 3.08% of the portfolio, ranked #7.

NIA Impact Advisors first reported a position in VRTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $8.8M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

NIA Impact Advisors held 15,490 shares of Vertex Pharmaceuticals worth $6.92M as of Q1 2026.
NIA Impact Advisors sold 2,148 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1M.
Vertex Pharmaceuticals made up 3.08% of NIA Impact Advisors's portfolio in Q1 2026, its #7 holding.
NIA Impact Advisors first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
NIA Impact Advisors's Vertex Pharmaceuticals position peaked at $8.8M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on NIA Impact Advisors's 13F filing for Q1 2026, filed 8 May 2026.